Cost-sharing for epilepsy-related prescription drugs and medical supplies limited.

2025-2026 Regular Session Introduced by Robert Bierman and 7 co-sponsors

The bill would limit cost-sharing for epilepsy-related prescriptions and related medical supplies in certain health plans, effective January 1, 2027.

Author added Curran

#drugsandmedicine #insurance-health

Purpose and intent

HF 3652 seeks to limit cost-sharing (co-pays and coinsurance) for epilepsy-related prescription drugs and related medical supplies. The bill defines targeted chronic diseases (including epilepsy) and designates related medical supplies that would be subject to cost-sharing limits. The goal is to reduce out-of-pocket costs for individuals managing epilepsy and associated chronic conditions through insured health plans.

Key provisions and changes

Targeted chronic diseases defined:

The bill identifies chronic diseases to which its provisions apply, explicitly including epilepsy (along with diabetes, asthma, and allergies requiring epinephrine auto-injectors).

Cost-sharing definition:

Retains CB terminology: “cost-sharing” means co-payments and coinsurance.

Scope of related medical supplies:

Expands or specifies items considered “related medical supplies” necessary to treat a chronic disease or administer a prescription drug. Items listed include:
Syringes
Insulin pens
Insulin pumps
Test strips
Glucometers
Continuous glucose monitors
Epinephrine auto-injectors
Asthma inhalers
These supplies are recognized as part of the package that could be eligible for cost-sharing limitations when used in conjunction with prescription drugs for chronic diseases.

Effective date and applicability:

The cost-sharing provisions would take effect January 1, 2027.
Applies to health plans offered, issued, or renewed on or after January 1, 2027.

Who/what would be affected

Health plans offered in Minnesota, including plans issued or renewed on or after January 1, 2027, would be subject to the bill’s cost-sharing limits for epilepsy-related prescription drugs and related medical supplies.

Enrollees with epilepsy or other defined chronic diseases (diabetes, asthma with epinephrine needs, and allergies requiring epinephrine) would potentially experience reduced out-of-pocket costs for:

Epilepsy-related prescription medications
Related medical supplies necessary to manage epilepsy or other identified chronic diseases

Manufacturers and providers of related medical supplies may see changes in cost-sharing dynamics for patients.

Procedural and timeline aspects

Introduction and committee status:

Bill introduced and referred to the Committee on Commerce Finance and Policy on February 23, 2026.

Amendments and sponsors:

Several co-sponsors listed; latest action shows additional authorship as of April 23, 2026.

Legislative timeline:

As of the summary, the bill has not yet passed; if enacted, the cost-sharing limits would become effective for plans starting January 1, 2027.

Notes

The bill text provided focuses specifically on Section 62Q.481, subdivision 2, clarifying definitions and the scope of related medical supplies related to chronic disease management.

The summary above reflects the information available in the bill text and action history; final details may be refined through committee amendments and floor action.

Bill